New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Mark Cuban: A Master Disrupter for American Health...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
High-speed imaging tracks live brain cell activity...
World is falling behind on UN's child mortality Sustainable ...
April 16,2026
Health literacy initiative improves discharge education, rea...
April 15,2026
Constipation is common, but with simple changes, you can man...
April 14,2026
Children and teenagers more open to meat free diets—but stru...
April 13,2026
3D-printed ATLAS platform helps model cancer cell clusters b...
April 12,2026
3 million-cell map shows menopause reshapes breast tissue, p...
April 11,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Today's News
Why is Alzheimer’s disease so difficult to treat? ...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Elucidating host-microbe interactions to address vector-borne diseases

Elucidating host-microbe interactions to address vector-borne diseases

by Serena Crawford,Yale UniversityGraphical abstract. Credit:Cell(2024). DOI: 10.1016/j.cell.2024.05.023In a new study, Yale researchers identify the targets in the human body to whi
Public Health & Prevention July 10,2024
Elucidating host-microbe interactions to address vector-borne diseases

Elucidating host-microbe interactions to address vector-borne diseases

by Serena Crawford,Yale UniversityGraphical abstract. Credit:Cell(2024). DOI: 10.1016/j.cell.2024.05.023In a new study, Yale researchers identify the targets in the human body to whi
Public Health & Prevention July 10,2024
Acupuncture may relieve pain-specific disability in degenerative lumbar stenosis

Acupuncture may relieve pain-specific disability in degenerative lumbar stenosis

by Elana GotkineFor patients with degenerative lumbar spinal stenosis (DLSS) and predominantly neurogenic claudication pain symptoms, acupuncture may relieve pain-specific disability, according to a s
Orthopedics & Sports medicine July 10,2024
Acupuncture may relieve pain-specific disability in degenerative lumbar stenosis

Acupuncture may relieve pain-specific disability in degenerative lumbar stenosis

by Elana GotkineFor patients with degenerative lumbar spinal stenosis (DLSS) and predominantly neurogenic claudication pain symptoms, acupuncture may relieve pain-specific disability, according to a s
Orthopedics & Sports medicine July 10,2024
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,
Oncology July 10,2024
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,
Oncology July 10,2024
Experts weigh in on new generation of weight loss medications

Experts weigh in on new generation of weight loss medications

by Julie Rafferty,Tufts UniversityCredit: Pixabay/CC0 Public DomainWe've all seen the ads and read about celebrities who have successfully lost weight using one of the new weight loss medica
Diabetes & Endocrinology July 10,2024
Experts weigh in on new generation of weight loss medications

Experts weigh in on new generation of weight loss medications

by Julie Rafferty,Tufts UniversityCredit: Pixabay/CC0 Public DomainWe've all seen the ads and read about celebrities who have successfully lost weight using one of the new weight loss medica
Diabetes & Endocrinology July 10,2024
Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

by Elana GotkineFor patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, accordi
Hepatobiliary&Pancreas Surgery July 10,2024
Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

by Elana GotkineFor patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, accordi
Hepatobiliary&Pancreas Surgery July 10,2024
Brain neurotransmitter receptor antagonist found to prevent opioid addiction in mice

Brain neurotransmitter receptor antagonist found to prevent opioid addiction in mice

byUniversity of California, Los AngelesSuvorexant blocked microglial activation in the hypothalamus and VTA. Credit:Nature Mental Health(2024). DOI: 10.1038/s44220-024-00278-2New res
Neurology July 10,2024
Brain neurotransmitter receptor antagonist found to prevent opioid addiction in mice

Brain neurotransmitter receptor antagonist found to prevent opioid addiction in mice

byUniversity of California, Los AngelesSuvorexant blocked microglial activation in the hypothalamus and VTA. Credit:Nature Mental Health(2024). DOI: 10.1038/s44220-024-00278-2New res
Neurology July 10,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu... ... Eye Infections (Updated) | Clinical Medicine ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com